DoseRoutine supplement library logoDoseRoutine
Pale round tablets on a dark surface lit by soft moonlight
DoseRoutine Ramelteon — Pale round tablets on a dark surface lit by soft moonlight. Original DoseRoutine photography.
medicationPrescription only (US)FDA-approved as Rozerem, a melatonin-receptor agonist, for insomnia characterized by difficulty with sleep onsetNot federally scheduled as a controlled substance, unlike many other prescription sleep medications

RamelteonBenefits, Dosage & Interactions

Also known as: Rozerem

Ramelteon, marketed under the brand name Rozerem, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty with sleep onset. It is typically taken in the evening. The reported plasma half-life is about 1 hours, which shapes dosing frequency.

How much Ramelteon do people take?

The meta-analysis pooled delirium-prevention trials using ramelteon 8 mg/day; the elderly residual-effects trial used a low 1.6 mg dose of ramelteon at bedtime. Route reported: Oral tablet in both cited study types. Frequency reported: Once daily, taken at bedtime, in the cited trials. These are amounts documented in the cited studies and labels for Ramelteon — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

See the full reported protocol and its sources

Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.

Evidence: Strong — 1 human randomized trial and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence

1 human randomized trial and regulatory approval on file.

Chemical structure of Ramelteon (PubChem CID 208902)
Structure via PubChem
Plasma half-life
1–2.6 h
Typical timing
in the evening
Default unit
mg

What published protocols report

Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.

Reported amounts
The meta-analysis pooled delirium-prevention trials using ramelteon 8 mg/day; the elderly residual-effects trial used a low 1.6 mg dose of ramelteon at bedtime[1][2]
Route studied
Oral tablet in both cited study types[1][2]
Frequency
Once daily, taken at bedtime, in the cited trials[1][2]
Cycle length
Delirium-prevention trials in the meta-analysis generally dosed for the duration of hospitalization; the residual-effects trial used single-night dosing[1][2]

Reported for Ramelteon in the cited sources. Published ranges are not dosing advice.

References & evidence

Documents the Ramelteon entry is written from. Each number matches an inline marker above.

  1. [1]Ramelteon for Delirium Prevention in Hospitalized Patients: An Updated Meta-Analysis and Trial Sequential Analysis of Randomized Controlled TrialsYu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Tu YK, et al. · Journal of Pineal Research · 2023 · Peer-reviewed · PMID 36726202
  2. [2]Residual Effects of Low Dose of Suvorexant, Zolpidem, and Ramelteon in Healthy Elderly Subjects: A Randomized Double-Blind StudyUemura SI, Imanishi A, Terui Y, Park I, Satake M, Han G, et al. · Neuropsychopharmacology Reports · 2022 · Peer-reviewed · PMID 35748642

References & Evidence

Sources on this page that document Ramelteon dosing, timing and safety.

  1. [1]National Center for Biotechnology Information View source
  2. [2]U.S. National Library of Medicine View source

Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.

What is Ramelteon?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.

Ramelteon, marketed under the brand name Rozerem, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty with sleep onset. Unlike some other sleep medications, ramelteon is not classified as a controlled substance, meaning it has a lower potential for abuse and dependence. Its mechanism of action is distinct from benzodiazepines and non-benzodiazepine hypnotics, primarily targeting melatonin receptors in the brain. It is typically taken shortly before bedtime. (Source: FDA label, DrugBank)

What does the research say about Ramelteon?

Tap a section to expand.

Ramelteon acts as a melatonin receptor agonist, specifically binding to and activating the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the brain. The SCN is the body's primary circadian pacemaker, responsible for regulating the sleep-wake cycle. By stimulating these melatonin receptors, ramelteon mimics the action of endogenous melatonin, the natural hormone that helps regulate sleep. This action is thought to promote the onset of sleep without directly inducing sedation or exhibiting significant effects on GABAergic systems, which are the primary targets of many other hypnotic medications. The MT1 receptor is believed to play a role in promoting sleep, while the MT2 receptor is thought to contribute to the regulation of circadian rhythms. (Source: DrugBank, PubChem)

Source for this section: Sources for How does Ramelteon work?: Jumps to this entry in the sources and references list at the end of the page.

The primary benefit of ramelteon is its ability to facilitate sleep onset in individuals experiencing insomnia. Clinical studies have shown that ramelteon can decrease the time it takes to fall asleep in adults with chronic insomnia. A key advantage highlighted in research (e.g., studies summarized by Cochrane reviews) is its mechanism of action, which bypasses GABAergic pathways. This difference leads to a lower risk profile concerning dependence and withdrawal symptoms compared to benzodiazepine and non-benzodiazepine hypnotics. Furthermore, ramelteon does not appear to exhibit significant rebound insomnia or withdrawal effects upon discontinuation, as described in various clinical reviews. It is also noted for not causing the 'hangover' effect or significant impairment in psychomotor function the next day, which can be a concern with some other sleep aids. (Source: Cochrane, DrugBank)

Clinical evidence supporting the efficacy of ramelteon for sleep onset insomnia comes from multiple randomized, placebo-controlled trials. For example, studies published in medical journals (reviewed by organizations like NIH) have consistently demonstrated that ramelteon significantly reduces latency to persistent sleep. Effects on sleep maintenance, while observed in some studies, are generally less pronounced than its impact on sleep onset. Long-term studies have also explored its sustained efficacy and safety profile over several months, indicating its utility for chronic insomnia treatment. Comparisons with other hypnotics highlight its distinct safety profile, particularly regarding the absence of abuse potential. The evidence base primarily supports its use for the specific indication of difficulty falling asleep. (Source: NIH, FDA label)

Commonly reported side effects of ramelteon include drowsiness, dizziness, fatigue, and nausea. Some individuals may also experience headache, common cold symptoms (nasopharyngitis), or insomnia. Less common but reported side effects include allergic reactions, such as swelling of the face, lips, tongue, or throat, which require immediate medical attention. In rare cases, complex sleep behaviors, such as sleep-driving, making phone calls, or preparing and eating food while not fully awake and having no memory of the event, have been reported. It is important to discontinue the medication and seek medical advice if such behaviors occur. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for What are the side effects of Ramelteon?: Jumps to this entry in the sources and references list at the end of the page.

Ramelteon should be used with caution in patients with severe hepatic impairment, as exposure to the drug is significantly increased in this population. It is not recommended for use in patients with severe sleep apnea or severe chronic obstructive pulmonary disease (COPD) due to potential for respiratory depression. Patients should be advised to avoid engaging in hazardous activities requiring complete mental alertness, such as operating machinery or driving a motor vehicle, after taking ramelteon, particularly until they know how the medication affects them. The medication should be taken immediately before attempting to sleep, and patients should be advised to allow at least 7 to 8 hours of sleep time. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for Who should avoid Ramelteon?: Jumps to this entry in the sources and references list at the end of the page.

Ramelteon is contraindicated in patients with a history of serious hypersensitivity reactions to ramelteon or any inactive ingredients in the formulation, including angioedema. It is also contraindicated in patients taking fluvoxamine, a strong CYP1A2 inhibitor, due to the potential for significantly increased exposure to ramelteon. Severe hepatic impairment is a contraindication as well. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for When should Ramelteon not be taken?: Jumps to this entry in the sources and references list at the end of the page.

Ramelteon should not be taken with fluvoxamine, an antidepressant, as fluvoxamine significantly increases ramelteon blood levels due to its inhibitory effect on the CYP1A2 enzyme. Concurrent use can lead to increased side effects. Caution is advised when ramelteon is used with other central nervous system (CNS) depressants, including alcohol, other hypnotics, sedatives, or anxiolytics, as additive CNS depressant effects may occur. Grapefruit juice can inhibit the metabolism of ramelteon and should be consumed with caution or avoided. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for What should you not mix with Ramelteon?: Jumps to this entry in the sources and references list at the end of the page.

Ramelteon is typically taken at bedtime, specifically within 30 minutes before going to bed. It is important to ensure that you have at least 7 to 8 hours available for sleep after taking the medication to avoid residual grogginess the next day. It can be taken with or without food. (Source: FDA label)

Source for this section: Sources for When should you take Ramelteon?: Jumps to this entry in the sources and references list at the end of the page.

Put it into practice

Reading about Ramelteon is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.

What interacts with Ramelteon?

Documented interactions for Ramelteon: the other compound, the severity and confidence of the interaction, what happens, and what to do.
Interacts withSeverityTypeWhat happensWhat to do
Any supplement + medicationNoteCategory ruleConfidence: theoreticalSome supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page.Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Any vitamin + medicationNoteCategory ruleConfidence: theoreticalCertain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page.Specific pairs are checked against a licensed source; confirm with your provider.

Frequently asked questions about Ramelteon

Ramelteon typically starts to work within 30 minutes of being taken, helping to initiate sleep. It should be taken right before you intend to go to bed.

Unlike some other sleep medications, ramelteon is not classified as a controlled substance and has shown a low potential for abuse or physical dependence. Studies (e.g., reviewed by DrugBank) indicate it does not produce significant withdrawal symptoms or rebound insomnia upon discontinuation.

Ramelteon is generally advised to avoid consuming alcohol while taking ramelteon. Alcohol can increase the sedative effects of the medication, leading to increased drowsiness, dizziness, and impaired coordination.

Ramelteon is a synthetic compound that specifically targets MT1 and MT2 melatonin receptors, mimicking the action of natural melatonin but through a defined pharmacological pathway. While exogenous melatonin supplements also work on these receptors, ramelteon is a prescription medication with a consistent dose and demonstrated efficacy in clinical trials for treating insomnia.

If you forget to take ramelteon at bedtime, and it is past your usual bedtime, it is usually best to skip the dose and not take it in the middle of the night. Taking it too late may result in residual effects the next day. Resume your regular dosing schedule the following night.

Interaction risk for Ramelteon comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Ramelteon is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 1 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Ramelteon with no sign-up.

There is no single answer for Ramelteon plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions

Pairing Ramelteon with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.

A short plasma half-life of roughly 1 hours is why protocols often split Ramelteon across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps

Because Ramelteon clears quickly (plasma half-life around 1 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.

For Ramelteon the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.

The meta-analysis pooled delirium-prevention trials using ramelteon 8 mg/day; the elderly residual-effects trial used a low 1.6 mg dose of ramelteon at bedtime. Route reported: Oral tablet in both cited study types. Frequency reported: Once daily, taken at bedtime, in the cited trials. These are amounts documented in the cited studies and labels for Ramelteon — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

Sources cited on this page

Specific documents referenced by the numbered markers above. Each number matches the marker in the text.

  1. PubChem CID 208902(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/208902
  2. MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a605038.html

Verify at

Publisher search links for Ramelteon. These are places to check the information — they are not citations, so they are not numbered.

DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.

What is the short answer on Ramelteon?

Plain-text summary, safe to quote verbatim:

Ramelteon, marketed under the brand name Rozerem, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty with sleep onset. It is typically taken in the evening. The reported plasma half-life is about 1 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/ramelteon

Ramelteon cheat sheet

DoseRoutine cheat sheet · Medication

Ramelteon

Ramelteon, marketed under the brand name Rozerem, is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty with sleep onset.

Evidence

Strong

1 human randomized trial and regulatory approval on file.

Studied range

The meta-analysis pooled delirium-prevention trials using ramelteon 8 mg/day; the elderly residual-effects trial used a low 1.6 mg dose of ramelteon at bedtime

Route

Oral tablet in both cited study types

Frequency studied

Once daily, taken at bedtime, in the cited trials

Half-life

1–2.6 h

Timing

in the evening

Prescription only (US)FDA-approved as Rozerem, a melatonin-receptor agonist, for insomnia characterized by difficulty with sleep onsetNot federally scheduled as a controlled substance, unlike many other prescription sleep medications

Key references

  1. Ramelteon for Delirium Prevention in Hospitalized Patients: An Updated Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials (2023)
  2. Residual Effects of Low Dose of Suvorexant, Zolpidem, and Ramelteon in Healthy Elderly Subjects: A Randomized Double-Blind Study (2022)

Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/ramelteon

Cite this page

Using this in an article, AI answer, or research note? Please attribute:

DoseRoutine. (2026). Ramelteon — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ramelteon
Canonical URL

What compounds are similar to Ramelteon?

Others in the medication category or studied for the same goals.

Track Ramelteon in DoseRoutine

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →

Latest research from DoseRoutine

Browse all DoseRoutine research updates

Track Ramelteon in your own routine

Add Ramelteon to your stack, get reminders at the right times, and see interaction notes with everything else you take. Free to start — no card needed.

Track Ramelteon freeSign in